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Most Escherichia coli resistant to quinolones are not haemolytic. The objective of this study was to determine the
phylogroup, clonal relationship, mechanism of quinolone resistance and virulence factors in 70 haemolytic E. coli
resistant to nalidixic acid. Sixty-six isolates contained the hlyA gene, belonged to phylogroup B2, and 61 of them
presented low-level resistance to fluoroquinolones. Four isolates presented high-level resistance to
fluoroquinolones, contained the clyA gene and were included in phylogroup D. One single isolate (phylogroup D,
with low level resistance to fluoroquinolones) contained both cytotoxins.
Keywords: Haemolysis, Escherichia coli, Quinolone resistance, hlyA, clyAEscherichia coli strains causing extraintestinal infec-
tions (ExPEC) express different virulence factors
(VF), including α-haemolysin (HlyA) and cytolysin A
(ClyA, SheA or HlyE), both of which can induce
osmotic lysis of erythrocytes (Kerényi et al. 2005).
However, quinolone-resistant clinical isolates of E.
coli ExPEC are frequently non-haemolytic (Horcajada
et al. 2005; Martínez-Martínez et al. 1999). This
may be related to the observation that strains of
phylogroup B2 and D usually contain more VF
(including haemolysins) than those of phylogroups A
and B1 (Clermont et al. 2000; Houdouin et al. 2007).
On the other hand, isolates of groups A and B1 are
more frequently resistant to quinolones than those
of phylogroup B2 and D (with the notable exception
of some particular multiresistant clones, such as the
O25:H4-B2-ST131 clone) (Houdouin et al. 2007;
Takahashi et al. 2009). Thus, a detailed analysis of
clinical isolates presenting the unusual association of
quinolone resistance and haemolysis production may
be helpful to understand the relationship between
virulence and resistance in E. coli.* Correspondence: alicia_marquez@hotmail.com
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reproduction in any medium, provided the origFrom November 2002 to March 2010, 33042
Escherichia coli were isolated from clinical samples in
our laboratory (University Hospital Marqués de Valdecilla,
Santander, Spain). Seventy (0.2% of all isolates) were
haemolytic and resistant to nalidixic acid. Organisms were
cultured from urine (63 isolates), blood (2), soft tissue
abscess (1), abdominal abscess (1), wound (1), tracheal
aspirate (1) or skin ulcer (1). Bacteria were identified
with the Microscan WalkAway 96 system (Dade
Behring, CA, USA). MICs of nalidixic acid (Sigma-
Aldrich, Madrid, Spain), ciprofloxacin (Sigma-Aldrich),
norfloxacin (Sigma-Aldrich) and levofloxacin (Aventis
Pharma, Madrid, Spain) were determined by broth
microdilution, according to CLSI guidelines (Clinical
and Laboratory Standards Institute 2011). Haemolysin
production was assessed in sheep blood agar (Oxoid,
Madrid, Spain). An organism was considered haemolytic
when a clear halo was observed around isolated colonies
after overnight incubation at 37°C. The phylogroup
was determined by multiplex PCR (Clermont et al.
2000). Clonal relationship was evaluated by repetitive
extragenic palindromic PCR (REP-PCR); isolates were
considered unrelated if more than two bands of
difference were observed. Additionally, 27 isolates
representative of the different patterns obtained by
REP-PCR (1–4 isolates per REP-PCR pattern), were. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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analyzed by Multilocus Sequence Typing (MLST)
according to the protocol specified at the E. coli
MLST website (http://mlst.ucc.ie/mlst/dbs/Ecoli). This
resulted in the recognition of 13 REP-PCR pattterns,
14 PFGE patterns and 11 sequence types (ST), which
combined allowed to define 15 distinct organisms. The
quinolone resistance-determining regions (QRDRs) of gyrA
and parC were amplified (Vila et al. 1996a; Vila et al.
1996b) and sequenced in the Molecular Genetics Unit of
the HUMV. The presence of genes coding for five major
horizontally transmissible quinolone resistance deter-
minants (qnrA, qnrB, qnrS, qepA, and aac-(60)-Ib-cr) was
investigated by multiplex PCR (Cano et al. 2009). The
presence of the hlyA and clyA genes was evaluated by PCR
(Kerényi et al. 2005). Additionally, 19 virulence-associated
genes (traT, iutA, bmaE, iroN, sfaS, afa/dra, ibeA, fyuA,
fimH, Pai, K1, K5, KpsMTII, KpsMTIII, cnf1, focG,
gafD, papC, sat) were analyzed in the previously
indicated 15 isolates (Johnson & Stell 2000; Bonacorsi
et al. 2003). The VF score of each isolate was
calculated as the number of VF genes for which the
isolate tested positive (Bert et al. 2008).
The distribution of MICs of the four evaluated
quinolones is presented in Additional file 1. According
to the CLSI breakpoints, 65 (92.8%), 64 (91.4%) and 66
(94.3%) out of the 70 isolates were susceptible to
ciprofloxacin, norfloxacin and levofloxacin, respectively.
When the breakpoints defined by EUCAST were consi-
dered, the percentages of susceptibility to ciprofloxacin,
norfloxacin and levofloxacin were 88.6%, 54.3% and
91.4%, respectively. All isolates contained one or two
mutations in gyrA alone or (in six cases) associated to a
mutation in parC (Table 1). The most common change
in GyrA was serine to leucine in position 83.
Plasmid-mediated quinolone resistance determinants
were not detected. Interestingly, although all our
haemolytic isolates contained one or more DNA-gyrase
mutations, most of them are defined as susceptible to
fluoroquinolones according to the CLSI breakpoints (Clin-
ical and Laboratory Standards Institute 2011), or even to
the more restrictive breakpoints defined by EUCAST
(European Committee on Antimicrobial Susceptibility
Testing 2012).
Sixty-six (94.3%) and five (7.2%) isolates corresponded
to phylogroups B2 and D. Most isolates of phylogroup
B2 belonged to ST73, ST12, ST372 or ST131, while
the majority of the isolates of the group D belonged
to ST350 (Table 1). Molecular typing has shown a
certain degree of clonal diversity among the isolates
we have evaluated, with some clones containing
single isolates and some other including multi-
ple isolates. According to these data, a qualitative
analysis indicates that our isolates do not representthe dissemination of only one single or just a few
clones.
Sixty-five (92.9%) isolates contained the hlyA gene,
four (5.7%) isolates contained the clyA gene and one
(1.4%) single isolate contained both hlyA and clyA. In a
previous study by Kerényi et al. on 540 extraintestinal
E. coli strains, the clyA gene was identified in 241
isolates and hlyA in 198 isolates (Kerényi et al. 2005);
these authors did not find an isolate simultaneously
containing both haemolysin genes and suggested
their possible incompatibility, which is in contrast
with our observation of an isolate with the two
haemolysin genes. MICs of ciprofloxacin for 61 out
of 65 (93.8%) isolates with only hlyA were ≤ 0.5 μg/
ml while MICs of this agent against the four isolates
containing only clyA were ≥ 8 μg/ml. The MICs of
the single isolate with both haemolysins was
0.125 μg/ml. It is difficult to determine if the
presence of clyA alone is more common in isolates
with high level fluoroquinolone resistance, as we
have found this association in just a small number of
isolates (all of them of ST 350). It would be possible
that this relationship is related to the phylogenetic
background of the isolates, as hlyA was linked to
phylogroup B2, while clyA was linked to phylogroup
D. Additional studies are in progress to evaluate this
observation in a large collection of E. coli consecu-
tively isolated from bacteremic episodes. This analysis
would also provide more data on the presence of
hlyA in strains with just low-level resistance to
fluoroquinolones.
The VF score was slightly higher for isolates of
phylogroup B2 (10.9) than for those of phylogroup D
(7.6). In the 15 isolates studied in detail, the most
frequent virulence-associated genes (Table 1) were
fimH (100%), cnf1 (87%), traT (80%), fyuA (80%) and
papC (80%). None of the isolates presented kpsMTIII.
Other genes such as PAI (73%), iroN (73%), K5 (67%),
kpsMTIII (67%), ibeA (53%), iutA (46.7%), sfaS
(33.3%), focG (26.6%), afa/dra (20%), sat (13.3%),
bmaE (6.6%), K1 (6.6%) and gafD (6.6%) were less
frequently detected. Isolates with clyA also contained
more frequently iutA and ibeA. Previous studies have
shown that the fimH and traT genes are more
frequently found in E. coli isolates (irrespective of
their susceptibility to quinolones) than other viru-
lence genes such cnf1 or hlyA (Takahashi et al. 2009;
Cooke et al. 2010). The prevalence of cnf1 in this
study, which is higher than that previously described
in isolates causing urinary and skin infections could
be explained by the association of cnf1 and hlyA in a
pathogenicity island, as previously reported (Johnson
& Stell 2000; Petkovsek et al. 2009; Schmidt &
Hensel 2004).
Table 1 Phylogroup (PhG), clonal relationship defined by REP-PCR patterns (REP), Pulsed-Field Gel Electrophoresis (PFGE), and Multilocus Sequence Typing
(MLST), MIC of quinolones, mutations in topoisomerase genes, and presence of haemolysins and virulence-associated genes in a representative set of isolates
MLST MIC (μg/ml) Mutations Haemolysins Virulence-associated genes
Isolate PhG REP (n) PFGE ST ST cplx NAL NOR CIP LEV gyrA parC hlyA clyA traT iroN ibeA fyuA cnf1 PAI papC K5 KpsMTII
Hly-557 D A (4) 1B 350 350 >512 >16 16 8 S83L D87N S80I - + - - + - - - - - -
Hly-1872 D 2 57 >512 >16 8 4 S83L D87N S80I - + + - + - - - - - -
Hly-263 D B (1) 3 405 405 32 0.5 0.125 0.125 D87G / + + + - + + + + + + +
Hly-520 B2 C (16) 4A 12 12 256 0.5 0.25 0.25 S83L / + - + + - + + + + + +
Hly-6129 B2 5 256 1 0.25 0.25 S83L / + - - + - + + + + - -
Hly-2304 B2 D (1) 6 599 12 >512 >16 1 1 S83L / + - + - - + + - + - -
Hly-4105 B2 E (19) 7 372 None 128 0.5 0.25 1 S83L / + - - + + + + + + - -
Hly-2425 B2 F (7) 8A 372 None 128 1 0.25 0.25 S83L / + - + + + + + + + + +
Hly-4530 B2 G (10) 9 73 73 128 0.5 0.25 0.25 S83L / + - + + - + + + + + +
Hly-3308 B2 H (19) 10C 73 73 64 0.5 0.125 0.125 D87Y / + - + + - + + + - + +
Hly-5126 B2 I (2) 11 127 None 64 1 0.25 0.5 D82N / + - + + - + + + + + +
Hly-3606 B2 J (1) 12 127 None 64 0.5 0.25 0.25 S83L / + - + + - + + + + + +
Hly-2605 B2 K (6) 13C 131 None 256 1 0.25 0.5 S83L / + - + + + + + + + + +
Hly-3438 B2 L (1) 13D 128 0.5 0.25 0.25 S83L / + - + + + + + + + + +
Hly-1248 B2 M (1) 14 537 14 >512 4 1 0.5 S83L S80R + - + + + - + - + + +
ST = Sequence Typing, ST cplx = Sequence Typing complexes, NAL = nalidixic acid, NOR = norfloxacin, CIP = ciprofloxacin, LEV = levoflofacin, S = Serine, L = Leucine, D = Aspartic acid, N = Asparagine, I = isoleucine,
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Additional file 1: Table 1. Distribution of absolute (and cumulative)
MICs (μg/ml) of four quinolones against 70 haemolytic E. coli isolates.
Values corresponding to resistance and intermediate susceptibility
(according to CLSI criteria) are shadowed in dark and pale grey,
respectively.
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